Replies to post #63532 on Anavex Life Sciences Corp (AVXL)

[ClosetInvestor]

I don't think fast track will be possible until we have data from the phase 2/3 trial. They won't allow FTD to be given based off the data of only 32 patients, IMO. The ODD for Rett Syndrome is big because that is 2-73s quickest path to the market and could possible lead to a FTD.